Core Insights - The US FDA has approved a higher-dose version of Spinraza, which is expected to sustain Biogen's position in the spinal muscular atrophy (SMA) market, generating over $1.5 billion annually [1][2] Group 1: Product Approval and Market Impact - The high-dose Spinraza regimen includes larger loading doses and higher maintenance levels, potentially addressing the "waning-off effect" in patients and improving response durability [2] - The therapy's rollout in Japan is ahead of expectations, with some patients returning to Spinraza after trying alternatives, and it has also received approvals in Europe and Switzerland [3] - The approval of high-dose Spinraza is seen as a bridge to next-generation therapies, such as salanersen, which may reach late-stage data by 2028 [4] Group 2: Competitive Landscape - Competition in the SMA market is expected to increase, but Spinraza's position remains strong, with data showing better motor function improvement when used with Spinraza compared to Roche's Evrysdi [6] - Roche has discontinued its emugrobart program, indicating challenges for some competing therapies [6] Group 3: Broader Portfolio and Future Growth - Biogen's diverse portfolio, including therapies like Leqembi and Vumerity, is seen as a foundation for potential stock gains from 2026 to 2027, with each therapy having over $1 billion in blockbuster potential [7] - The company aims to have one to two pipeline products approved to drive topline revenue growth, with management actively pursuing assets valued up to $5 billion to $6 billion [8] Group 4: Pricing and Market Performance - While pricing for high-dose Spinraza is not disclosed, improved efficacy could justify a premium during the initial treatment phase [9] - Biogen's shares increased by 2% to $187 following the news [9]

Supernus Pharmaceuticals FY Conference Summary Company Overview - **Company**: Supernus Pharmaceuticals (NasdaqGM: SUPN) - **Date of Conference**: March 11, 2026 - **Key Speaker**: Jack A. Khattar, President and CEO Key Accomplishments in 2025 - **Sage Therapeutics Acquisition**: Significant milestone for the company, enhancing the product portfolio with the addition of Zurzuvae, which is expected to be a major growth driver [2][4] - **FDA Approvals and Product Launches**: Successful launch of ONAPGO, which exceeded expectations and contributed to revenue growth [4][5] - **Record Revenue**: 2025 marked a record year for revenue, driven by the transition from legacy products to new offerings [4] Growth Drivers - **Product Portfolio**: Four main growth drivers identified: - **Qelbree**: ADHD treatment, showing 21% growth in 2025 and 18% growth in Q4 [5][23] - **Gocovri**: Parkinson's treatment, with 14% growth in prescriptions [37] - **Zurzuvae**: Postpartum depression treatment, unique in its rapid efficacy [38] - **ONAPGO**: Strong demand despite supply constraints, with forms submitted increasing from 1,300 to 1,800 [10][49] Market Performance - **Stock Performance**: The stock increased by 80% over a six-month period, reflecting market recognition of the company's portfolio reconfiguration [12] - **Market Share**: Qelbree achieved 931,000 prescriptions in 2025, indicating significant market potential within a total market of 111 million prescriptions [27] Supply Chain and Production - **Supply Constraints**: ONAPGO faced supply issues due to overwhelming demand and shared production lines with other clients [48] - **Future Supply Plans**: Plans to secure a second source of supply by 2027 to alleviate production constraints [49] Financial Guidance for 2026 - **Revenue Expectations**: Projected revenue between $840 million and $870 million, representing a growth of 32%-37% [50] - **Operating Earnings**: Expected to remain flat year-over-year at $140 million to $170 million due to ongoing investments in new products [58] Research and Development Pipeline - **SPN-817**: Phase 2 trial for epilepsy, expected data in 2027 [68][72] - **SPN-820**: Phase 2 trial for major depressive disorder, anticipated to recruit faster than epilepsy trials [74] - **SPN-443**: Early-stage stimulant for ADHD, with ongoing studies to assess its safety and efficacy [78] Strategic Outlook - **M&A and R&D**: The company emphasizes the importance of both mergers and acquisitions and research and development for future growth [93] - **Market Education**: Ongoing efforts to educate physicians and patients about new treatment options, particularly for postpartum depression [61][66] Conclusion - **Future Potential**: The company believes it is at the beginning of a transformative phase, with a clean balance sheet and a focus on both organic growth and strategic acquisitions [93]

Company Overview - Biogen Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on therapies for neurological and neurodegenerative diseases, with a market cap of $27.7 billion [1]. Market Position - Biogen is classified as a large-cap stock, with its market cap exceeding $10 billion, highlighting its size and influence in the drug manufacturing industry [2]. - The company is expanding its pipeline into immunology and rare diseases, utilizing advanced modalities like antisense oligonucleotides (ASOs) to meet significant medical needs [2]. Stock Performance - Currently, Biogen's shares are trading 5.5% below their 52-week high of $202.41, reached on February 6 [3]. - Over the past three months, Biogen's shares have increased by 10.8%, outperforming the State Street Health Care Select Sector SPDR ETF (XLV), which experienced a slight decline [3]. - Year-to-date, Biogen's shares are up 8.6%, while XLV has fallen by 1.4% [5]. - In the last 52 weeks, Biogen's stock has surged by 33.1%, significantly outpacing XLV's 4.6% increase [5]. Earnings Performance - Following a stronger-than-expected Q4 earnings release on February 6, Biogen's shares rose by 8.5% [7]. - The company's revenue for Q4 was $2.3 billion, a 7.1% decline year-over-year, but it exceeded the analyst estimate of $2.2 billion [7]. - Adjusted EPS for the quarter was $1.99, surpassing consensus expectations of $1.63, attributed to strong performance from newer products like Leqembi, Skyclarys, Zurzuvae, and Qalsody, which collectively generated over $1 billion in annual revenue [7]. Competitive Analysis - Biogen has outperformed its competitor Amgen Inc. (AMGN), which saw an 18.4% increase over the past 52 weeks, although Biogen has lagged behind AMGN's 15.3% year-to-date rise [8]. - Analysts maintain a moderately optimistic outlook for Biogen, with a consensus rating of "Moderate Buy" from 35 analysts and a mean price target of $206.66, indicating an 8.6% premium to current price levels [8].

Core Insights - AbbVie reported strong fourth-quarter and full-year 2025 results, with significant revenue growth driven by its immunology portfolio and steady contributions from its neuroscience segment [1][2]. Neuroscience Segment Performance - The neuroscience segment generated $10.8 billion in revenue for 2025, accounting for approximately 18% of AbbVie's total revenues, reflecting a nearly 20% year-over-year increase [2][8]. - Key products in this segment, including Botox Therapeutic, Vraylar, Qulipta, and Ubrelvy, experienced double-digit sales growth, while the newer therapy Vyalev contributed $482 million in sales [2][8]. - For 2026, AbbVie anticipates neuroscience revenues to reach $12.5 billion, indicating a 16% growth from 2025, with expectations for Vyalev to exceed $1 billion in global sales [3][8]. Product Pipeline and Future Growth - AbbVie is preparing to expand its neuroscience portfolio with a new oral therapy for Parkinson's disease, tavapadon, which is currently under FDA review [4]. - If approved, tavapadon could enhance AbbVie's presence in the Parkinson's disease market and strengthen the long-term growth potential of its neuroscience segment [4]. Competitive Landscape - Competitors in the neuroscience space include Biogen and Johnson & Johnson, both of which are also focusing on expanding their neuroscience offerings [5][6]. - Biogen is diversifying its portfolio due to declining revenues in its multiple sclerosis franchise, while Johnson & Johnson continues to grow its neuroscience products through acquisitions and new therapies [5][6]. Valuation and Market Performance - AbbVie shares are currently trading at a price/earnings (P/E) ratio of 15.61, which is below the industry average of 18.26, although above its five-year mean of 13.73 [9]. - The Zacks Consensus Estimate for AbbVie's 2026 EPS has increased from $14.31 to $14.54, indicating positive market sentiment [11].

Financial Data and Key Metrics Changes - Supernus achieved record total revenues of $719 million in 2025, representing a 27% increase compared to the previous year [17] - The company reported a GAAP net loss of $38.6 million for 2025, compared to a net earnings of $73.9 million in 2024 [18] - For the fourth quarter of 2025, total revenue was $211.6 million, a 21% increase year-over-year [13] Business Line Data and Key Metrics Changes - Revenues from four growth products (Qelbree, Proquarius, Zurzuvae, and ONAPGO) accounted for approximately 76% of total revenues in Q4 2025 [4] - ONAPGO generated net sales of $8.9 million in Q4 2025, up from $6.8 million in Q3 2025, with total net sales of $17.3 million for its first year [5] - Zurzuvae had collaboration revenues of $32.8 million in Q4 2025, with U.S. sales increasing approximately 187% compared to Q4 2024 [7] - Qelbree exceeded $300 million in net sales for 2025, delivering 26% growth compared to 2024 [8] Market Data and Key Metrics Changes - The number of prescribers for ONAPGO grew by 28% in Q4 2025 compared to Q3 2025, with prescriptions increasing by 29.6% [6] - The number of prescribers for Zurzuvae doubled in 2025 compared to 2024, with total prescriptions increasing by over 150% [8] Company Strategy and Development Direction - The company is focused on corporate development and exploring strategic opportunities to strengthen its position in the CNS market through revenue-generating products and late-stage pipeline candidates [11] - Supernus aims to continue growing its core business despite the loss of exclusivity on Trokendi XR and Oxtellar XR [4] - The company plans to maintain a diversified portfolio of growth products to mitigate reliance on any single product [78] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving total revenues of $840 million to $870 million for 2026, with expectations of $45 million to $70 million in net sales from ONAPGO [20] - The company anticipates combined R&D and SG&A expenses to range from $620 million to $650 million for 2026 [20] - Management highlighted the importance of resolving supply constraints for ONAPGO to meet demand and clear backlogs [29] Other Important Information - The company had approximately $309 million in cash equivalents and marketable securities as of December 31, 2025, down from $454 million in 2024 [19] - Supernus is actively working on R&D programs, including trials for SPN-820 and SPN-817, with data expected in 2027 [74] Q&A Session Summary Question: ONAPGO sales guidance and supplier capacity - Management confirmed that the current supplier can meet the sales guidance of $45 million to $70 million for ONAPGO through 2026, with a second supplier expected to come online in 2027 [23] Question: ONAPGO demand and backlog clearance - Management stated that the current supplier will help clear the backlog and meet ongoing demand throughout 2026 [29] Question: R&D prioritization post-Sage acquisition - Management indicated that early-stage assets will undergo preclinical work, and prioritization will be based on market opportunity and ROI [30] Question: Pricing expectations for ONAPGO - Management estimated that the average annual cost for ONAPGO could be around $100,000 per patient, depending on usage [38] Question: Gross-to-net expectations for ONAPGO - Management expects gross-to-net deductions for ONAPGO to be in the range of 20% to 30%, typically higher in Q1 [67] Question: Commercial strategy for Zurzuvae - Management emphasized the need to build market awareness and confidence among physicians for Zurzuvae, while also focusing on both existing and new prescribers [60][62]

Financial Data and Key Metrics Changes - Supernus achieved record total revenues of $719 million for the full year 2025, representing a 27% increase compared to the previous year [17] - The fourth quarter of 2025 saw total revenue of $211.6 million, a 21% increase year-over-year, with net product sales of $158.1 million [13] - GAAP net loss for the full year 2025 was $38.6 million, or a loss of $0.68 per diluted share, compared to a GAAP net earnings of $73.9 million, or $1.32 per diluted share in 2024 [18] Business Line Data and Key Metrics Changes - Revenues from the four growth products (Qelbree, Proquarius, Zerzura, and ONAPGO) accounted for approximately 76% of total revenues in Q4 2025 [4] - ONAPGO generated net sales of $8.9 million in Q4 2025, up from $6.8 million in Q3 2025, with total net sales of $17.3 million for its first year [5] - Zurzuvae had collaboration revenues of $32.8 million in Q4 2025, with U.S. sales increasing approximately 187% compared to the same period in 2024 [7] - Qelbree exceeded $300 million in net sales for 2025, delivering 26% growth compared to 2024 [8] Market Data and Key Metrics Changes - The number of prescribers for ONAPGO grew by 28% in Q4 2025 compared to Q3 2025, with prescriptions increasing by 29.6% [6] - The number of prescribers for Zurzuvae doubled in 2025 compared to 2024, with total prescriptions increasing by more than 150% [8] Company Strategy and Development Direction - The company successfully executed an integrated acquisition of Sage Therapeutics and obtained FDA approval for ONAPGO, launching it in the Parkinson's market [4] - Corporate development remains a top priority, with a focus on additional strategic opportunities to strengthen future growth in CNS through revenue-generating products or late-stage pipeline candidates [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to meet demand for ONAPGO through existing suppliers and anticipated a smooth transition to a second supplier in 2027 [23][50] - The company expects total revenues for 2026 to range from $840 million to $870 million, with guidance assuming $45 million to $70 million in net sales from ONAPGO [20] Other Important Information - Combined R&D and SG&A expenses for 2025 were $591.8 million, up from $430.4 million in 2024, primarily due to acquisition-related costs [18] - The company had approximately $309 million in cash equivalents and marketable securities as of December 31, 2025, down from $454 million the previous year [19] Q&A Session Summary Question: ONAPGO supply and sales potential - Management confirmed that the current supplier can meet the $45 million-$70 million sales guidance for ONAPGO, with plans for continuity of supply into 2027 [23] Question: ONAPGO demand and backlog clearance - Management indicated that the current supplier will help clear the backlog and meet ongoing demand throughout 2026 [29] Question: R&D prioritization post-Sage acquisition - Management stated that early-stage assets will undergo preclinical work, and prioritization will be based on market opportunity and ROI [30] Question: Gross-to-net expectations for ONAPGO - Management expects gross-to-net for ONAPGO to be in the range of 20%-30%, typically higher in Q1 [66]

Financial Data and Key Metrics Changes - Supernus achieved record total revenues of $719 million for the full year 2025, representing a 27% increase compared to the previous year [16] - For Q4 2025, total revenue was $211.6 million, a 21% increase year-over-year, and a 34% increase when excluding net product sales of Trokendi XR and Oxtellar XR [13][16] - GAAP net loss for the full year 2025 was $38.6 million, or a loss of $0.68 per diluted share, compared to a GAAP net earnings of $73.9 million, or $1.32 per diluted share in 2024 [17] - Adjusted operating earnings for the full year 2025 were $158.7 million, down from $183.7 million in 2024 [18] Business Line Data and Key Metrics Changes - Revenues from the four growth products (Qelbree, Proquarius, Zerzura, and ONAPGO) accounted for approximately 76% of total revenues in Q4 2025 [4] - ONAPGO generated net sales of $8.9 million in Q4 2025, up from $6.8 million in Q3 2025, with total net sales for its first year at $17.3 million [5] - Zurzuvae had collaboration revenues of $32.8 million in Q4 2025, with U.S. sales increasing approximately 187% compared to Q4 2024 [6] - Qelbree exceeded $300 million in net sales for 2025, delivering 26% growth compared to 2024 [8] Market Data and Key Metrics Changes - The number of prescribers for ONAPGO grew by 28% in Q4 2025 compared to Q3 2025, with prescriptions increasing by 29.6% [5] - The number of prescribers for Zurzuvae doubled in 2025 compared to 2024, with total prescriptions increasing by more than 150% [6] - GOCOVRI reached net sales of $146 million for the full year 2025, a 12% increase compared to 2024 [10] Company Strategy and Development Direction - The company aims to continue growing its core business while exploring corporate development opportunities to strengthen its position in the CNS market [11][76] - Supernus is focused on revenue-generating products and late-stage pipeline candidates, with a strategic emphasis on expanding its portfolio beyond CNS into areas like women's health [72] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving total revenues of $840 million to $870 million for 2026, with expectations of $45 million to $70 million in net sales from ONAPGO [19] - The company anticipates combined R&D and SG&A expenses to range from $620 million to $650 million for 2026 [19] - Management highlighted the importance of maintaining a strong balance sheet with no debt, providing financial flexibility for future growth opportunities [18] Other Important Information - The company initiated a Phase IIb trial for SPN-820 and is progressing with ongoing trials for SPN-817, with data expected in 2027 [11][71] - Supernus has made significant investments in R&D and SG&A, with combined expenses reaching $591.8 million for the full year 2025 [16] Q&A Session Summary Question: ONAPGO supply and sales potential - Management confirmed that the current supplier can meet the $45 million-$70 million sales guidance for ONAPGO, with plans for continuity of supply into 2026 [21] Question: ONAPGO demand and patient enrollment - Management indicated that the current supplier will help clear the backlog and support new patient initiations, with ongoing processing of enrollment forms [28] Question: R&D prioritization post-Sage acquisition - Management stated that early-stage assets will undergo preclinical work, with prioritization based on market opportunity and ROI [29] Question: Zurzuvae commercial strategy - Management emphasized the need to build market awareness and confidence among physicians to drive prescriptions for Zurzuvae [59] Question: Gross-to-net expectations for ONAPGO - Management expects gross-to-net for ONAPGO to be in the range of 20%-30%, typically higher in Q1 [66]

Core Insights - Biogen Inc. reported better-than-expected fourth-quarter earnings with adjusted EPS of $1.99, surpassing the consensus estimate of $1.59 [1] - The company generated revenues of $2.28 billion, exceeding the consensus of $2.20 billion, although this represents a 7% decline on both a reported and constant currency basis [1] Drug Performance - Fiscal 2025 revenue from growth products increased by 19% year-over-year, which helped offset the decline in revenue from multiple sclerosis products, excluding Vumerity [2] - Leqembi, an Alzheimer's drug, generated collaboration revenue of $47 million, with in-market sales reaching approximately $134 million, reflecting a 54% increase [3] - Multiple sclerosis revenue totaled $917 million, down 14% year-over-year (15% decline on a constant currency basis), with Tysabri sales decreasing from $415.4 million to $397.5 million [3] Rare Disease Revenue - Revenue from rare diseases decreased by 4% year-over-year to $514.6 million, with Spinraza's revenue declining from $421.4 million to $356.2 million [4] - Spinraza's fourth-quarter revenue fell by 15% year-over-year, influenced by shipment timing outside the U.S., while full-year revenue was down 2% [4] New Product Contributions - Skyclarys, a drug for Friedreich's ataxia, reported revenues of $133.4 million during the quarter, up from $102.2 million a year ago [5] - Skyclarys saw a 30% increase in global patients on therapy in 2025, with U.S. revenue of approximately $89 million driven by demand growth [6] - Zurzuvae, a postpartum depression drug, achieved fourth-quarter revenue of approximately $66 million, indicating strong demand growth [6] - Vumerity's revenue grew by 3% year-over-year in the fourth quarter to $181.1 million [6] Management Commentary - The President and CEO of Biogen highlighted that the 2025 performance was driven by nearly $1 billion in revenue from LEQEMBI, SKYCLARYS, ZURZUVAE, and QALSODY, along with pipeline progression and the resilience of the MS franchise [7]

Core Viewpoint - Biogen Inc. is a prominent biotechnology company specializing in therapies for neurological and neurodegenerative diseases, facing competition from major pharmaceutical companies in the neurology sector [1] Financial Performance - Biogen reported Q4 2025 earnings per share (EPS) of $1.99, exceeding the Zacks Consensus Estimate of $1.61, but reflecting a 42% decline from the previous year [3][6] - The company's total revenue for Q4 2025 was $2.28 billion, surpassing the Zacks Consensus Estimate of $2.21 billion, despite a 7% year-over-year decline [3][6] Revenue Drivers - The revenue decline was primarily due to weaker sales of key multiple sclerosis (MS) drugs such as Tecfidera and Tysabri, as well as the spinal muscular atrophy (SMA) drug Spinraza [4] - Increased sales from newer drugs like Leqembi, Skyclarys, and Zurzuvae partially offset the revenue decline from established products [4] Stock Performance - Following an optimistic 2026 adjusted EPS guidance projected between $15.25 and $16.25, Biogen's stock price rose to $201.18, marking an increase of 8.53% or $15.82 [4][6] - The stock has fluctuated between a low of $184.60 and a high of $202.41, with the latter being the highest price over the past year [5] Analyst Rating - On February 6, 2026, BMO Capital adjusted its rating for Biogen to "Market Perform," maintaining a "hold" action, while raising the price target from $165 to $196, indicating a more optimistic outlook [2]

Core Insights - Biogen reported fourth-quarter 2025 adjusted EPS of $1.99, exceeding the Zacks Consensus Estimate of $1.61, despite a 42% year-over-year decline in earnings [2][10] - Total revenues for the quarter were $2.28 billion, down 7% year over year, but above the Zacks Consensus Estimate of $2.21 billion, driven by weak sales of key drugs [3][10] Revenue Breakdown - Product sales decreased to $1.67 billion, a 9% decline year over year [4] - Revenues from anti-CD20 therapeutic programs increased by 12% to $521 million, including royalties from Roche's Ocrevus and Biogen's share of other drugs [4] - Contract manufacturing and royalty revenues fell 66% to $44 million, while Alzheimer's collaboration revenues rose to $47 million from $27 million year-over-year [5][6] Multiple Sclerosis (MS) Drug Performance - MS revenues totaled $917 million, down 14% year over year, impacted by generic competition for Tecfidera [7] - Tecfidera sales plummeted 51% to approximately $112 million, missing estimates, while Tysabri sales fell 4% to $397.5 million, beating estimates [8] - Vumerity sales increased by 3% to $181 million, but also missed estimates [7] Rare Disease Drug Performance - Spinraza sales declined over 15% to $356 million, missing estimates [9] - Skyclarys generated over $133 million in sales, up nearly 31% year over year, driven by demand growth [11] - Qalsody added $25 million in sales compared to $12 million in the previous year [11] Cost and Expense Management - Adjusted R&D expenses decreased by 6% to $478 million due to cost-saving initiatives [14] - Adjusted SG&A expenses rose 1% to $678 million, reflecting higher costs for new product launches [14] 2025 Financial Performance - Biogen's total revenues for 2025 reached $9.89 billion, surpassing estimates and showing a 2% year-over-year increase [15] - Earnings per share were $15.28, down 7% year over year, but above estimates [15] 2026 Guidance - Total revenues are expected to decline by a mid-single-digit percentage in constant currency terms, with adjusted EPS projected between $15.25 and $16.25, above consensus estimates [16] - Gross margin is expected to remain flat, with R&D and SG&A costs anticipated to be consistent year over year [17] Market Outlook - Despite challenges in the MS franchise and declining Spinraza sales, newer therapies like Leqembi, Skyclarys, and Zurzuvae are gaining traction [18][21] - The company is focused on building a multi-franchise portfolio through internal development and collaborations, with key pipeline products having a peak revenue potential of $14 billion [21][22]